Entweder 10000% oder Totalverlust

ragingbull.lycos.com/mboard/boards.cgi?board=CALY&read=5720

zugeschaut aber i believe i can fly.... he he

guten morgen caly fans! kommt hinter euren büschen heraus & let's dance calypso!!!

mehr sogi net

seit heute wieder im xetra-handel, was das wohl zu bedeuten hat !!!

heutiger start USA 0,049 $, nicht aufgeben leute, der tag wird kommen .....

ich mein das fest wird geil !!!!!!!!!!!!!!!!!

da setzt wohl ikönchen auf alles.

war 3 monate gar kein xetra-handel, dachten wohl die aktie macht pleite

und jetzt heute plötzlich wieder, komisch oder !!!!!!!!!!1

"We are thrilled to hear that HCCI had such a positive experience with urine testing and plans to continue to incorporate our tests in their future programs," said Nancy Katz, Calypte's President and CEO. "HCCI's event is an excellent example of how urine HIV testing can be successfully executed for programs that take place in a non-clinic setting and has demonstrated that our urine tests are a viable option for getting people tested so that more will know their HIV status."

About Harlem Congregations for Community Improvement (HCCI):

HCCI, located in Harlem, New York, was formed in 1986 as a diverse inter-faith consortium of more than 90 congregations. It is a large multi-service organization, with five major divisions, one of which is the Department of Health and Wellness Strategies. It was established to revitalize the physical, economic, cultural and spiritual conditions of the Harlem community. This goal is being accomplished by developing low to moderate income housing throughout central Harlem, creating supportive health and human service programs and facilities, expanding cultural programs, assisting families and individuals living with HIV/AIDS with housing, group support, advocacy and prevention programs. HCCI is a certified service partner of the Balm in Gilead organization.

About Calypte Biomedical:

Calypte Biomedical Corporation headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte's tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples. The company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners. Current product labeling including specific product performance claims can be found on our website at www.calypte.com.

Statements in this press release that are not historical facts are forward-looking statements, including statements regarding announcements of financial results and presentations by the Company. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K/A(No.3) for the year ended December 31, 2001 and its subsequent filings with the SEC.



CONTACT:          Calypte Biomedical Corporation
                 Pamela South, 510/749-5100
                 psouth@calypte.com
                 or
                 Lippert/Heilshorn & Associates
                 Investor Relations:
                 Brendan Lahiff/Kirsten Chapman, 415/433-3777
                 brendan@lhai-sf.com

URL:              www.businesswire.com
Today's News On The Net - Business Wire's full file on the Internet
with Hyperlinks to your home page.

Copyright (C) 2003 Business Wire.  All rights reserved.

aber reicht das um aus diesen Sumpf zu emtweichen???

hat jemand den aktuellsten kurs??

viel calypso & spass!

bin aber dise Woche zur hälfte in WC die scheinen seit gestern gut abzugehn
0,138  heute hoffen wir das eine von beiden hoch geht!Party so oder so

                            Grüße

jetzt siehts aber braun aus,sollte schnell was passieren, sonst siehts echt böse aus, bleibe aber trozdem drinn, versprochen.


gruß Grenke

hey leute, nicht in die hose machen, caly hat schon schlimmeres überstanden !!

caly kommt noch & sonst, c'est la börsen vie & wer fett verdient soll auch fett brennen, das ist mein motto!!!"

ist jemand schon lange bei caly??

warten wir mal ab !!!!!!!!!!!!!!!!1

z.b. ranbaxy hat eine zulassung von der fda bekommen,
vielleicht nur ein kleiner hoffnungsfunke, aber caly wartet ja auch noch, grins

positive meldungen sind wichtig weil der umsatz sonst sehr klein wird

bekam nur 48000 was soll uns das sagen, bitte bitte bitte lieber gott

ich will noch die 42000 dann bin ich reich !!!!!!!!!!!!!!!!!!!!

yippie

aber über Ami Kursen zu Kaufen ? Mut ?
                                           Gruß

ich will meine 90000 heute noch voll haben,
9,3% plus ist das alles, es geht wieder runter hoff ich mal,
und dann wart ich bis mai und hab dann viel geld oder nichts, grins-mal-frech

ratet mal, *ggg